Qinhuangdao: the world's largest neutral pharmaceutical glass production base
with the strong support and help of the Hebei provincial government, Qingao flame retardant polyurethane foam insulation material key technology through expert evaluation, Huangdao municipal government, Qinhuangdao Development Zone Management Committee, Hebei Financial Investment Group, industrial and Commercial Bank of China Hebei Branch, China CITIC Bank Hebei branch and other financial institutions, At 11:11 a.m. on July 28, 2015, Jialong holding group cooperated with 13 famous glass equipment companies such as German sorg, the world's top kiln supplier, to build the world's largest neutral pharmaceutical glass production base with a daily output of 300 tons in Qinhuangdao Economic and Technological Development Zone
with the increasing development of the global pharmaceutical industry and the rapid development of science and technology, in the face of today's international market of economic integration, the requirements for the packaging of pharmaceutical products, especially pharmaceutical glass packaging products, are becoming higher and higher. At present, low borosilicate glass is mostly used in pharmaceutical packaging glass products in China. Practice has proved that the chemical properties of this kind of glass material are unstable. As a drug packaging material, long-term use is easy to cause chemical reactions between drugs and glass within the validity period, which not only affects or changes the quality of drugs, but also seriously hinders the process of internationalization of drugs in China
neutral pharmaceutical glass (also called 5.0 glass or first-class water-resistant pharmaceutical glass or class a material in China) of the international general standard for pharmaceutical packaging is a general pharmaceutical glass packaging material recognized and determined to be used in compliance all over the world. This kind of neutral pharmaceutical glass has stable chemical structure, excellent expansion coefficient, acid and alkali corrosion resistance, cold and hot temperature change resistance, high mechanical strength, and will not produce miscible reaction with drugs within the validity period of drugs, and will not change the quality of drugs. Because of its excellent chemical stability and thermal stability, neutral pharmaceutical glass is favored by the international pharmaceutical industry, and has been widely used in the field of pharmaceutical packaging. At present, the international pharmaceutical packaging standards are based on neutral pharmaceutical glass as the executive standard. China's relevant departments are considering plans to gradually restrict the use of metal particles and eliminate the traditional pharmaceutical glass products that have been used in China, and formulate and update China's national standards for pharmaceutical glass according to international standards
at present, the application of high-end pharmaceutical glass in China is all dependent on foreign imports, with an annual growth rate of no less than 20%. As of 2014, the total demand of the international market has exceeded 500000 tons, and the annual growth rate is not less than 15%. The international market has long been monopolized by kenberg of the United States and Schott of Germany. The incremental market gap is huge, and the market prospect is very broad
neutral pharmaceutical glass packaging products, as the standard pharmaceutical packaging materials commonly used in international pharmaceutical packaging, belong to high borosilicate glass products. Neutral drugs will also give the extruder industry endless development power. The quantitative production and processing of glass has become the bottleneck of China's pharmaceutical glass industrialization and development because it is difficult to melt, shape and clarify, which seriously hinders and affects the development process of China's pharmaceutical internationalization. Based on the development and demand of the market, Jialong holding group seized the opportunity to objectively demonstrate, relying on the R & D and production team and experience of Jialong holding group in the glass industry for more than 20 years, it worked together with 13 famous glass equipment companies, including the world's top kiln supplier German sorg company, the heat treatment equipment supplier Czech sklostroj company, the famous glass forming equipment supplier Italian Olivotto company and German waltec company, After multi-party demonstration, it was finally determined to build the world's largest neutral pharmaceutical glass production base with a daily output of 300 tons in Qinhuangdao Economic and Technological Development Zone, and the construction was started in Qinhuangdao on July 28, 2015. The project includes all the manufacturing processes of quartz sand raw material purification, glass melt melting, tube drawing and molding, pharmaceutical glass products production, high-precision testing and automatic aseptic packaging
the project of China Pharmaceutical glass production base belongs to the industry encouraged by the state. The clean and environmental protection energy of international standards is applied in the whole production process. The production process, formula and emission during the production process are formulated in strict accordance with the best industrial emission standards of EU and Germany. With a total area of 18 hectares, it is planned to build 30 neutral pharmaceutical glass production lines by adding graphene to high-molecular materials to improve the properties of conductive plastics and coating graphene film on the surface of conductors to improve the conductivity and other related properties. The China Pharmaceutical glass production base project is jointly funded by Jialong holding group and Wanjing group with a total investment of 10billion yuan. The first phase of the project is planned to be put into operation in December 2016, In the next five years, after all production lines are put into operation, the annual output of pharmaceutical glass will reach 35 billion yuan, profits and taxes will reach 2 billion yuan, more than 8000 new jobs will be created, and China's high-end neutral pharmaceutical glass has been completely dependent on imports for 60 years. Within five years, China will realize the upgrading of pharmaceutical glass for the benefit of the Chinese people. While filling the gap in the industrialized mass production of pharmaceutical glass in China, Qinhuangdao will also become the largest production base of high-end pharmaceutical glass in the world, laying a solid industrial foundation and making new contributions to the internationalization of China's pharmaceutical industry
global glass () Department
LINK
Copyright © 2011 JIN SHI